Key Reminder for Iovance Biotherapeutics Investors
Attention Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors! If you have incurred losses exceeding $100,000 due to stock fluctuations, a crucial opportunity to engage with legal proceedings is at hand. Former Attorney General and partner at Kahn Swick & Foti, LLC, Charles C. Foti, Jr. is reaching out to those affected. The firm underscores the importance of acting swiftly regarding the lead plaintiff deadline in the pending class action lawsuit.
Class Action Lawsuit Details
Investors are invited to file lead plaintiff applications, with the final date set for July 15, 2025. The lawsuit revolves around securities purchased between May 9, 2024, and May 8, 2025. This period is critical as it marks the timeline for assessing alleged misrepresentation and failure to disclose pivotal information by Iovance executives.
Important Actions to Take
Should you have invested in Iovance during this period and wish to understand your rights regarding potential recourse for financial losses, free consultations are available. Interested parties can connect with KSF Managing Partner Lewis Kahn toll-free or through email. Engaging with KSF could provide insights into the potential impacts of this lawsuit and your standing.
Nature of the Allegations
The core of the lawsuit asserts that Iovance and its top executives failed to transparently communicate essential information during the specified period, thereby violating federal securities laws. Investors are particularly concerned following the financial disclosures that reflected a staggering drop in revenue forecasts.
Impact on Stock Prices
When Iovance released its first quarter earnings report for 2025 on May 8, it reported a significant revenue drop to $49.3 million, compared to $73.7 million in the previous quarter. This led to a revised guidance for total product revenue for the fiscal year 2025, slashed from estimates between $450 million and $475 million down to a range of $250 million to $300 million. Following this announcement, the price of Iovance's shares plummeted by almost 45%, triggering alarm among investors.
Understanding Your Rights
If you're one of the investors affected by these developments, it's imperative to stay updated. Engaging with legal representatives ensures you understand your rights and potential ways to recover losses incurred. Remember, it is vital to act before the deadline to secure your opportunity to be a lead plaintiff.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is a respected securities litigation law firm, noted for its commitment to representing investors in their pursuit of justice and recovery from investment losses. Their office areas span multiple states, providing comprehensive support to both public and private investors facing challenges due to corporate malfeasance. Kahn Swick & Foti has been highlighted as one of the top firms in the nation for its impact in securities class action litigation.
Frequently Asked Questions
What is the lead plaintiff deadline for the lawsuit?
The deadline to file lead plaintiff applications is July 15, 2025.
Who can participate in the class action lawsuit?
Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be eligible.
What are the allegations against Iovance Biotherapeutics?
The company and its executives are accused of failing to disclose vital information, which resulted in misleading investors during the class period.
How did the stock price react to the company’s financial disclosures?
The stock price fell about 44.8% following the company's disappointing financial reports.
Where can I find more information about Kahn Swick & Foti?
Details regarding KSF and their services can be found by reaching out to them directly or visiting their official website.
